Working… Menu

Additive Homeopathy in Cancer Patients (HIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01509612
Recruitment Status : Completed
First Posted : January 13, 2012
Last Update Posted : August 16, 2018
Information provided by (Responsible Party):
Michael Frass, Medical University of Vienna

Brief Summary:

The investigators aim to investigate the validity of their previous results in a randomized prospective, placebo-controlled, double-blind, multicenter controlled evaluation of questionnaires in patients with advanced malignant tumors. The investigators plan to compare the treatment outcome (quality of life and survival) in tumor patients, receiving standard or "add-on" homeopathic treatment.

The null hypothesis is that "add-on" homeopathic treatment does not create a benefit for cancer patients. In addition the investigators evaluate survival time.

Condition or disease Intervention/treatment Phase
Malignant Tumors Drug: Additive classical homeopathy Drug: Homeopathic Placebo globules Phase 2 Phase 3

Detailed Description:
The EORTC-QLQ-C30 as well as a VAS scale for subjective well-being will be filled out by the patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Study Evaluating Quality of Life in Patients With Advanced Malignant Lung Tumors With or Without "add-on" Homeopathy
Study Start Date : January 2011
Actual Primary Completion Date : March 31, 2018
Actual Study Completion Date : July 31, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Additive homeopathy in cancer patients
Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
Drug: Additive classical homeopathy
Homeopathic remedies every 2 to 3 months
Other Name: Classical homeopathic remedies

Placebo Comparator: Additive homeopathic placebo globules
Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
Drug: Homeopathic Placebo globules
Homeopathic placebo globules every 2 to 3 months
Other Name: Homeopathic Placebo globules looking identical to verum

No Intervention: No intervention
No intervention

Primary Outcome Measures :
  1. Life quality [ Time Frame: 7 years ]
    Life quality is evaluated by using the results of the EORTC-QLQ-C30 questionnaire

Secondary Outcome Measures :
  1. Survival [ Time Frame: 7 years ]
    Survival is evaluated by assessing time in months from diagnosis until death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed consent
  • Clinical diagnosis of advanced tumor stages of glioblastoma IV, metastasized sarcoma, as well as non small-cell lung carcinoma (NSCLC) IV.

Exclusion Criteria:

  • Pregnant patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01509612

Layout table for location information
Medical University Vienna
Vienna, Austria, A 1090
Sponsors and Collaborators
Medical University of Vienna
Layout table for investigator information
Principal Investigator: Michael Frass, Prof. Dr. Medical University Vienna

Additional Information:
Layout table for additonal information
Responsible Party: Michael Frass, Principal Investigator, Prof. Dr., Director, Outpatient Unit Homeopathy in tumor patients, Medical University of Vienna Identifier: NCT01509612     History of Changes
Other Study ID Numbers: 5
First Posted: January 13, 2012    Key Record Dates
Last Update Posted: August 16, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Michael Frass, Medical University of Vienna:
additive homeopathy
patients with advanced malignant tumors
Additional relevant MeSH terms:
Layout table for MeSH terms